Muramatsu Takashi, Kadomatsu Kenji
Department of Health Science, Faculty of Psychological and Physical Science, Aichi Gakuin University, 12 Araike, Iwasaki-cho, Nisshin, Aichi, 470-0195, Japan.
Br J Pharmacol. 2014 Feb;171(4):811-3. doi: 10.1111/bph.12571.
Midkine is a multifunctional factor and has anti-apoptotic, migration-promoting, angiogenic, anti-microbial and other activities. Midkine ameliorates ischemic injury in the heart and brain, enhances oocyte maturation, and is involved in neurogenesis. On the other hand, midkine is an important factor in the etiology of various diseases, especially those with inflammatory backgrounds. Furthermore, midkine is overexpressed in most malignant tumors and plays roles in their invasive phenotypes as well as in their resistance to chemotherapeutics. Therefore, midkine itself is expected to be useful for the treatment of brain and heart diseases, while midkine inhibitors are promising for the treatment of malignant tumors, multiple sclerosis, restenosis, renal diseases, hypertension and osteoporosis. Blood levels of midkine are also expected to be helpful as disease markers, especially as cancer markers.
This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.
中期因子是一种多功能因子,具有抗凋亡、促进迁移、血管生成、抗菌等活性。中期因子可改善心脏和大脑的缺血性损伤,促进卵母细胞成熟,并参与神经发生。另一方面,中期因子是各种疾病病因中的一个重要因素,尤其是那些具有炎症背景的疾病。此外,中期因子在大多数恶性肿瘤中过度表达,并在其侵袭表型以及对化疗药物的抗性中发挥作用。因此,中期因子本身有望用于治疗脑和心脏疾病,而中期因子抑制剂有望用于治疗恶性肿瘤、多发性硬化症、再狭窄、肾脏疾病、高血压和骨质疏松症。中期因子的血液水平也有望作为疾病标志物,尤其是作为癌症标志物发挥作用。
本文是关于中期因子的主题部分的一部分。要查看本部分的其他文章,请访问http://dx.doi.org/10.1111/bph.2014.171.issue-4。